Split History
ETFs Holding ARWR »    ARWR Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arrowhead Pharmaceuticals develops drugs to treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference mechanism to induce knockdown of target genes. Co.'s pipeline includes ARO-HBV for chronic hepatitis B virus, ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARO-F12 for hereditary angioedema and thromboembolic disorders, ARO-HIF2 for renal cell carcinoma, and ARO-AMG1 for an undisclosed genetically validate cardiovascular target. According to our ARWR split history records, Arrowhead Pharmaceuticals has had 1 split.
ARWR split history picture
Arrowhead Pharmaceuticals (ARWR) has 1 split in our ARWR split history database. The split for ARWR took place on January 15, 2004. This was a 1 for 65 reverse split, meaning for each 65 shares of ARWR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 15.3846153846154 share position following the split.

When a company such as Arrowhead Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ARWR split history from start to finish, an original position size of 1000 shares would have turned into 15.3846153846154 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arrowhead Pharmaceuticals shares, starting with a $10,000 purchase of ARWR, presented on a split-history-adjusted basis factoring in the complete ARWR split history. ARWR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/26/2007
End date: 04/25/2017
Start price/share: $6.11
End price/share: $1.52
Dividends collected/share: $0.00
Total return: -75.12%
Average Annual Total Return: -12.98%
Starting investment: $10,000.00
Ending investment: $2,488.05
Years: 10.01
Date Ratio
01/15/20041 for 65
ARWR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ASMB Split History
ASTM Split History
ATE Split History
ATEC Split History
ATOS Split History
ATRC Split History
ATRI Split History
AVXL Split History
AZN Split History
BAX Split History

Rexahn Pharmaceuticals, Inc. (RNN)
Immune Pharmaceuticals Inc. (INMP)
DryShips Inc. (DRYS)
STRATA Skin Sciences, Inc. (SSKN)
Quantum Corp. (QTM)
German American Bancorp, Inc. (GABC)
Pacific Energy Development (PED)
The GEO Group, Inc. (GEO)
Copart, Inc. (CPRT)
HEICO Corporation (HEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ARWR Insider Buying

ARWR Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.